It has been suggested by epidemiological [11], [12], [13] and clinical studies [14], [16], [24], [40] that treatment with a GLP-1 receptor agonist, such as liraglutide, diminishes the risk of cardiovascular disease in patients with Type 2 diabetes. Here, GLP1R is linked to cardiovascular disorder.